ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Dr. Greg Riely: How Should We Approach Acquired Resistance to Targeted Therapies in Advanced NSCLC?"
Episode Synopsis
Dr. Greg Riely from Memorial Sloan-Kettering reviews strategies for managing acquired resistance to EGFR inhibitors and other targeted therapies in advanced non-small cell lung cancer.
More episodes of the podcast GRACEcast Cancer 101 Audio
Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
31/07/2014
Management of Rare Kidney Tumors
29/07/2014
NanoString Treatment for Kidney Cancer
24/07/2014
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?
22/07/2014
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
17/07/2014
What is PD1 and PDL1 in Kidney Cancer?
15/07/2014
In God we trust